title: Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization:  do we need more evidence?
authors.forename: Timothy Y Y
authors.initials: TY
authors.lastname: Lai
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058452:Axial Length, Eye / Q000473:pathology; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D047728:Myopia, Degenerative / Q000188:drug therapy* / Q000503:physiopathology; D056687:Off-Label Use; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab